Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$121.28 USD
-0.19 (-0.16%)
Updated Sep 12, 2024 04:00 PM ET
After-Market: $118.20 -3.08 (-2.54%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth A Momentum B VGM
Brokerage Reports
Neurocrine Biosciences, Inc. [NBIX]
Reports for Purchase
Showing records 201 - 220 ( 316 total )
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Continued Ingrezza Momentum Complemented by Progress in PD and CAH Programs
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Underlying Business Continues to Outperform as Pipeline and Cash Position Offer Multiple Sources of Upside Optionality
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Looking Past Ingrezza Seasonality, We See a Number of Fundamental Drivers of Value Ahead; Reit Buy and $102 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
The Positive CAH Interim Data Should Clear the Way for the Regulatory Talk; Reit Buy and $102 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
As Commercial Advances Continue, Believe CAH Data Can Be Meaningful Catalyst; Reit Buy and $102PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Continue to Believe 2019 Value Proposition Is Attractive; Reit Buy and $102 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Our Thoughts Following the Miss in Tourette Syndrome T-Force Gold Trial; Lowering PT to $102
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Momentum on Multiple Fronts; Reit Buy and Raising PT to $162
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Utilizing Growth of Ingrezza Revenue to Invest in Ingrezza
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
2018 Ought to Be a Catalyst-Filled Year; Reit Buy and $139PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Ingrezza Strength Reaffirms Our Bull Case; Reit Buy and Raising PT to $139
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Strong Ingrezza Launch Lifts the Tone for Quarters Ahead
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Strong Ingrezza Launch Lifts the Tone for Quarters Ahead
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A